Gate2brain

Gate2Brain is a biotechnology company founded in 2019 in Barcelona, Spain, by Marc Ramis Castelltort, Esther Riambau, and Gloria Sanclimens Perez De Rozas.

The company is focused on developing a technology platform to overcome the challenge of delivering drugs across biological barriers, particularly the blood-brain barrier (BBB). This barrier protects the brain from harmful substances but also prevents the entry of many potentially effective drugs for neurological disorders. Gate2Brain's technology aims to facilitate the passage of therapeutic molecules into the brain, opening up new treatment possibilities for a range of central nervous system (CNS) diseases.

The company's approach is based on a proprietary peptide-based platform. These peptides act as "keys" to unlock the "gates" of the BBB, allowing for the transport of various drug molecules. The technology is designed to be versatile, with potential applications for a wide array of therapeutics, from small molecules to larger biologics. By enabling targeted drug delivery to the brain, Gate2Brain's platform could improve the efficacy and reduce the side effects of treatments for conditions like Alzheimer's disease, Parkinson's disease, and brain tumors.

Gate2Brain operates on a business-to-business (B2B) model, partnering with pharmaceutical and biotechnology companies. These partners can use Gate2Brain's technology to enhance their own drug candidates, improving their ability to reach the intended target in the brain. The company's revenue is generated through a combination of licensing fees, milestone payments, and royalties on the sales of drugs that incorporate its delivery platform.

Keywords: biotechnology, drug delivery, blood-brain barrier, central nervous system, therapeutics, peptide platform, neurodegenerative diseases, oncology, licensing, pharmaceutical partnerships